MET and non-small cell lung carcinoma: Savolitinib, a novel potent and selective MET-inhibitor that is under evaluation in a Phase II study on METex14-mutated NSCLC (NCT02897479), has demonstrated promising anti-tumor activity and a durable response in a preliminary analysis [31].